Nuvilex, Inc. and Diabetes Research Institute Have Similar Approach to Islet Cell Transplantation
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 04/18/13 -- Nuvilex, Inc. (OTCQB: NVLX) has "Cell-in-a-Box," the Diabetes Research Institute has BioHub. One is cell encapsulation technology, and the other is an integrated spongy wafer. While they have different names and a different structure, the idea is the same -- building a fully protected home to house pancreatic islet (insulin-producing) cells for transplantation into diabetics.
Both Nuvilex and the Diabetes Research Institute (DRI) have identified the problem and clearly have a game plan in place to address it. Between "Cell-in-a-Box" and BioHub there is real hope on the horizon for diabetics who currently engage in a daily routine of checking their blood-glucose levels many times, giving themselves insulin either through injections or with an insulin pump, watching what they eat, monitoring how much or how little exercise they're getting and the list goes on and on. While the islet cells in a diabetic's pancreas no longer sense glucose and therefore the pancreas doesn't produce insulin, the pump or self injections provide the body with the insulin needed to stay healthy.
Well, help is on the way! Whether it will be Nuvilex's "Cell-in-a-Box" or the DRI's BioHub or both, the many scientists working to offer what Nuvilex calls a type of "artificial pancreas" and DRI calls a "mini-organ" are on the right track with their similar approaches to the same problem. Islet cell transplantation is nothing new, but long term housing of the cells is the goal. The director of the DRI, Dr. Camillo Ricordi, says for his organization's BioHub to be successful, the structure must prove it "restores natural insulin production and normalizes blood sugar levels without imposing other risks."
Groundbreaking work in a high profile study called the "Edmonton Protocol" showed that pancreatic islet cell transplantations could hold the key to a game-changing diabetes therapy. However, the problem in that study was...
Continue reading this article at
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.
Contact:
Stock House Group
646-397-4020
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.04.2013 - 12:30 Uhr
Sprache: Deutsch
News-ID 250359
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nuvilex, Inc. and Diabetes Research Institute Have Similar Approach to Islet Cell Transplantation"
steht unter der journalistisch-redaktionellen Verantwortung von
Nuvilex, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
